Search

Author/Creator Weisel, K.

1. P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY. (23rd June 2022)

Authors:
Oriol, A.; Dimopoulos, M.; Schjesvold, F.; Beksac, M.; Yagci, M.; Larocca, A.; Guo, S.; Mu, Y.; Hong, K.; Dhanasiri, S.; Richardson, P.; Weisel, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
792
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL. (23rd June 2022)

Authors:
Leypoldt, L.; Gavriatopoulou, M.; Besemer, B.; Salwender, H.; Raab, M.-S.; Nogai, A.; Khandanpour, C.; Runde, V.; Zago, M.; Martus, P.; Goldschmidt, H.; Bokemeyer, C.; Dimopoulos, M.; Weisel, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
816
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Usmani, S. Z.; Mielnik, M.; Koh, Y.; Alonso Alonso, A.; Leleu, X.; Quach, H.; Min, C.-K.; Janowski, W.; Abdallah, A.-O.; Garg, M.; Sandhu, I.; Ocio San Miguel, E. M.; Oriol, A.; Rodriquez-Otero, P.; Ramasamy, K.; Weisel, K.; Besemer, B.; Cavo, M.; Zhou, X. L.; Kaisermann, M. C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
832
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Weisel, K.; Mateos, M.-V.; Vincent, L.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Jagannath, S.; Lin, Y.; Thilakarathne, P.; Ghilotti, F.; Diels, J.; Haefliger, B.; Hague, C.; Gonzalez, A.; Schecter, J. M.; Gries, K. S.; Strulev, V.; Nesheiwat, T.; Pacaud, L.; Einsele, H.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
861
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY. (23rd June 2022)

Authors:
Suvannasankha, A.; Bahlis, N.; Trudel, S.; Weisel, K.; Koenecke, C.; Oriol, A.; Voorhees, P. M.; Alonso, A. A.; Callander, N. S.; Mateos Manteca, M. V.; Reddy, N.; Hakim, S.; Patel, N.; Williams, D.; Jewell, R. C.; Zhou, X.; Gupta, I.; Nooka, A. K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
830
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA. (23rd June 2022)

Authors:
Hillengass, J.; Cohen, A. D.; Delforge, M.; Einsele, H.; Goldschmidt, H.; Weisel, K.; Raab, M.-S.; Scheid, C.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Yeh, T.-M.; Mistry, P.; Roccia, T.; Corsale, C.; Akram, M.; Pacaud, L.; Nesheiwat, T.; Agha, M.; Cohen, Y. C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
849
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY. (23rd June 2022)

Authors:
Weisel, K.; Wadlund, A.; Gungor, G.; Dergarabetian, E.; Pacheco, C.; Masurkar, N.; Rodriguez-Otero, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
863
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. (23rd June 2022)

Authors:
Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Borgsten, F.; Usmani, S. Z.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
826
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN'S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS. (23rd June 2022)

Authors:
Weisel, K.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Mateos, M.-V.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; Ammann, E.; Kobos, R.; Smit, J.; Parekh, T.; Slavcev, M.; Moreau, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
862
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Delforge, M.; Moreau, P.; Einsele, H.; De Stefano, V.; Lindsey-Hill, J.; Vincent, L.; Mangiacavalli, S.; Perrot, A.; Ocio, E.; ten Seldam, S.; '. Groen-Damen, E. I.; Semerjian, M.; Strulev, V.; Schecter, J. M.; Roccia, T.; Gries, K. S.; Nesheiwat, T.; Wapenaar, R.; Mateos, M.-V.; Weisel, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
850
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗